Detalles de la búsqueda
1.
A Prediction Model for Successful Increase of Adalimumab Dose Intervals in Patients with Crohn's Disease: Secondary Analysis of the Pragmatic Open-Label Randomised Controlled Non-inferiority LADI Trial.
Dig Dis Sci;
2024 Apr 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-38594435
2.
Cross-cultural translation and validation of the IBD-control questionnaire in The Netherlands: a patient-reported outcome measure in inflammatory bowel disease.
Scand J Gastroenterol;
56(2): 155-161, 2021 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-33300822
3.
Inflammatory bowel disease patients provide reliable self-reported medical information: A multicentre prospective pharmacovigilance monitoring system.
Pharmacoepidemiol Drug Saf;
30(4): 520-524, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33219593
4.
Limited relevance and progression of histological alterations in the liver during thioguanine therapy in inflammatory bowel disease patients.
Scand J Gastroenterol;
54(6): 753-760, 2019 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-31203688
5.
Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI).
Gut;
63(2): 292-9, 2014 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-23525574
6.
Treatment of bone loss in osteopenic patients with Crohn's disease: a double-blind, randomised trial of oral risedronate 35â mg once weekly or placebo, concomitant with calcium and vitamin D supplementation.
Gut;
63(9): 1424-30, 2014 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-24146170
7.
Long-term effectiveness and safety of ustekinumab in Crohn's disease: a prospective cohort study.
Eur J Gastroenterol Hepatol;
35(3): 261-269, 2023 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36708296
8.
External Validity and Consistency over Time of Patient Segmentation Based on Disease Acceptance and Perceived Control in Inflammatory Bowel Disease.
J Gastrointestin Liver Dis;
32(3): 306-314, 2023 09 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-37774220
9.
Thioguanine is Effective as Maintenance Therapy for Inflammatory Bowel Disease: A Prospective Multicentre Registry Study.
J Crohns Colitis;
17(6): 933-942, 2023 Jun 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-36702552
10.
Increased versus conventional adalimumab dose interval for patients with Crohn's disease in stable remission (LADI): a pragmatic, open-label, non-inferiority, randomised controlled trial.
Lancet Gastroenterol Hepatol;
8(4): 343-355, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36736339
11.
Exposure to Thioguanine During 117 Pregnancies in Women With Inflammatory Bowel Disease.
J Crohns Colitis;
17(5): 738-745, 2023 May 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36521000
12.
Cost-Effectiveness Analysis of Increased Adalimumab Dose Intervals in Crohn's Disease Patients in Stable Remission: The Randomized Controlled LADI Trial.
J Crohns Colitis;
17(11): 1771-1780, 2023 Nov 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-37310877
13.
De-escalation of biological therapy in inflammatory bowel disease patients following prior dose escalation.
Eur J Gastroenterol Hepatol;
34(5): 488-495, 2022 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34974465
14.
Impact of Biological Therapies and Tofacitinib on Real-world Work Impairment in Inflammatory Bowel Disease Patients: A Prospective Study.
Inflamm Bowel Dis;
28(12): 1813-1820, 2022 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35134917
15.
Lower Risk of Recurrence with a Higher Induction Dose of Mesalazine and Longer Duration of Treatment in Ulcerative Colitis: Results from the Dutch, Non-Interventional, IMPACT Study.
J Gastrointestin Liver Dis;
31(1): 18-24, 2022 03 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-35306553
16.
Discrepancy between patient- and healthcare provider-reported adverse drug reactions in inflammatory bowel disease patients on biological therapy.
United European Gastroenterol J;
9(8): 919-928, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34077634
17.
Adverse Drug Reactions from Real-World Data in Inflammatory Bowel Disease Patients in the IBDREAM Registry.
Drug Saf;
44(5): 581-588, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33538994
18.
Clinical Outcomes of Covid-19 in Patients With Inflammatory Bowel Disease: A Nationwide Cohort Study.
J Crohns Colitis;
15(4): 529-539, 2021 Apr 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33079178
19.
Role of ASCA and the NOD2/CARD15 mutation Gly908Arg in predicting increased surgical costs in Crohn's disease patients: a project of the European Collaborative Study Group on Inflammatory Bowel Disease.
Inflamm Bowel Dis;
13(7): 874-81, 2007 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-17278126
20.
Disease outcome of inflammatory bowel disease patients: general outline of a Europe-wide population-based 10-year clinical follow-up study.
Scand J Gastroenterol Suppl;
(243): 46-54, 2006.
Artículo
en Inglés
| MEDLINE | ID: mdl-16782622